title: Quantitative characterization of the mechanism of action and impact of a 'proteolysis-permitting' anti-PCSK9 antibody.
abstract: A recent report described a novel mechanism of action for an anti-proprotein convertase subtilisin-kexin type 9 (PCSK9) monoclonal antibody (LY3015014, or LY), wherein the antibody has improved potency and duration of action due to the PCSK9 epitope for LY binding. Unlike other antibodies, proteolysis of PCSK9 can occur when LY is bound to PCSK9. We hypothesized that this allowance of PCSK9 cleavage potentially improves LY efficiency through two pathways, namely lack of accumulation of intact PCSK9 and reduced clearance of LY. A quantitative modeling approach is necessary to further understand this novel mechanism of action. We developed a mechanism-based model to characterize the relationship between antibody pharmacokinetics, PCSK9 and LDL cholesterol levels in animals, and used the model to better understand the underlying drivers for the improved efficiency of LY. Simulations suggested that the allowance of cleavage of PCSK9 resulting in a lack of accumulation of intact PCSK9 is the major driver of the improved potency and durability of LY. The modeling reveals that this novel 'proteolysis-permitting' mechanism of LY is a means by which an efficient antibody can be developed with a total antibody dosing rate that is lower than the target production rate. We expect this engineering approach may be applicable to other targets and that the mathematical models presented herein will be useful in evaluating similar approaches.
authors.affiliation: a Lilly Research Laboratories, Eli Lilly and Company , Indianapolis , IN , USA.
authors.forename: Ryan J
authors.initials: RJ
authors.lastname: Hansen
authors.affiliation: a Lilly Research Laboratories, Eli Lilly and Company , Indianapolis , IN , USA.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Berna
authors.affiliation: a Lilly Research Laboratories, Eli Lilly and Company , Indianapolis , IN , USA.
authors.forename: Andrea E
authors.initials: AE
authors.lastname: Sperry
authors.affiliation: a Lilly Research Laboratories, Eli Lilly and Company , Indianapolis , IN , USA.
authors.forename: Thomas P
authors.initials: TP
authors.lastname: Beyer
authors.affiliation: a Lilly Research Laboratories, Eli Lilly and Company , Indianapolis , IN , USA.
authors.forename: Victor J
authors.initials: VJ
authors.lastname: Wroblewski
authors.affiliation: a Lilly Research Laboratories, Eli Lilly and Company , Indianapolis , IN , USA.
authors.forename: Krista M
authors.initials: KM
authors.lastname: Schroeder
authors.affiliation: b Eli Lilly and Company (Ret.).
authors.forename: Patrick I
authors.initials: PI
authors.lastname: Eacho
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics*; D008078:Cholesterol, LDL / Q000378:metabolism; D006801:Humans; D008252:Macaca fascicularis; D051379:Mice; D008962:Models, Theoretical; D000091362:PCSK9 Inhibitors; D059748:Proteolysis / Q000187:drug effects; D000071449:Proprotein Convertase 9
chemical_list: D000911:Antibodies, Monoclonal; D008078:Cholesterol, LDL; D000091362:PCSK9 Inhibitors; C000610655:frovocimab; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9
keywords: Antibody; PCSK9; PKPD; pharmacodynamics; pharmacokinetics; proteolysis-permitting